Carcinoma in situ of the urinary bladder
- Authors: Korneyev I.A.1, Batmaev D.B.1
-
Affiliations:
- St.-Petersburg State Medical University named after acad. I. P. Pavlov
- Issue: Vol 2, No 1 (2012)
- Pages: 29-31
- Section: Articles
- URL: https://journals.eco-vector.com/uroved/article/view/2549
- DOI: https://doi.org/10.17816/uroved2129-31
- ID: 2549
Cite item
Abstract
Carcinoma in situ of the urinary bladder is a wide spread urological malignancy with unpredictable clinical course and prognosis. While diagnostic modalities develop the treatment and follow-up regimen recommended have been standardized.
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Igor Alekseevich Korneyev
St.-Petersburg State Medical University named after acad. I. P. Pavlov
Email: iakorneyev@yandex.ru
doctor of medical science, professor. Department of Urology
Dmitriy Borisovich Batmaev
St.-Petersburg State Medical University named after acad. I. P. Pavlov
Email: iakorneyev@yandex.ru
student. St.-Petersburg State Medical University named after acad. I. P. Pavlov
References
- Аль-Шукри С. Х., Данильченко Д. И., Корнеев И. А., Аль-Шукри А. С. Прогностическая ценность флуоресцентной цистоскопии с использованием 5-аминолевулиновой кислоты у больных раком мочевого пузыря // Нефрология. 2005. Т. 9. № 4. С. 80–84.
- Аль-Шукри С. Х., Корнеев И. А., Кассем А. М., Козлов В. В. Применение адъювантной внутрипузырной иммунотерапии вакциной БЦЖ «Имурон» и прогноз у больных с поверхностными переходноклеточными карциномами мочевого пузыря // Тезисы докладов четвертого международного урологического симпозиума «Диагностика и лечение рака мочевого пузыря». Нижний Новгород. 2005. C. 10.
- Аль-Шукри С. Х., Эмануэль В. Л., Корнеев И. А. и др. Прогностическая ценность цитологического исследования осадка мочи у больных раком мочевого пузыря // Нефрология. 2006. № 10 (2). C. 101–104.
- Ткачук В. Н., Данильченко Д. И., Аль-Шукри А. С. Место оптико-когерентной томографии в диагностике рака мочевого пузыря // Урология. 2009. № 2 C.42–44.
- Berger A. P., Steiner H., Stenzl A. et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study // Urology. 2003. № 61. P. 338–341.
- De Reijke T. M., Kurth K. H., Sylvester R. J. et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906) // J. Urol. 2005. № 173. P. 405–409.
- D’Hallewin M. A., Bezdetnaya L., Guillemin F. Fluorescence detection of bladder cancer: a review // Eur. Urol. 2002. № 42. P. 417–425.
- Epstein J. I., Amin M. B., Reuter V. R., Mostofi F. K., the Bladder Consensus Conference Committee. The World Health Organization / International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder // Am. J. Surg. Path. 1998. № 22. P. 1435–1448.
- Glas A. S., Roos D., Deutekom M., Zwinderman A. H., Bossuyt P. M. M., Kurth K. H. Tumor markers in the diagnosis of primary bladder cancer. A systematic review // J. Urol. 2003. № 169. P. 1975–1982.
- Jakse G. et al., members of the EORTC GU Group. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 // Eur. Urol. 2001. № 40. P. 144–150.
- Kaasinen E., Wijkstrom H., Malmstrom P. U. et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study // Eur. Urol. 2003. № 43 P. 637–645.
- Kurth K. H., Schellhammer P. F., Okajima E. et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra // Int. J. Urol. 1995. № 2 (Suppl 2). P. 8–22.
- Lamm D. L. Carcinoma in situ // Urol. Clin. N. Am. 1992. № 19. P. 499–508.
- Lamm D. L., Herr H. W., Jakse G. et al. Updated concepts and treatment of carcinoma in situ // Urol Oncol. 1998. № 4. P. 130–138.
- Lamm D. L., van der Meijden A. P. M., Akaza H. et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? // Int. J. Urol. 1995. № 2 (Suppl 2). P. 23–25.
- Lamm D. L., van der Meijden A. P. M., Morales A. et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer // J. Urol. 1992. № 147. P. 596–600.
- Lopez-Beltran A., Bassi P. F., Pavone-Macaluso M., Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis // Eur. Urol. 2004. № 45. P. 257–266.
- O’Donnell M. A. et al., the National Bacillus Calmette-Guerin / Interferon phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2b for superficial bladder cancer // J. Urol. 2004. № 172. P. 888–893.
- Sarosdy M. F., Manyak M. J., Sagalowsky A. I. et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin // Urology. 1998. № 51. P. 226–231.
- Sharkey F. E., Sarosdy M. F. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ // J. Urol. 1997. № 157. P. 68–70.
- Solsona E., Iborra I., Dumont R. et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer // J. Urol. 2000. № 164. P. 685–689.
- Solsona E., Iborra I., Ricos J. V. et al. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management // Urology. 1997. № 49. P. 347–352.
- Steinberg G., Bahnson R., Brosman S. et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder // J. Urol. 2000. № 163. P. 761–767.
- Witjes J. A. Bladder carcinoma in situ in 2003: state of the art // Eur. Urol. 2004. № 45. P. 142–146.
- Zaak D., Hungerhuber E., Schneede P. et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions // Cancer. 2002. № 95. P. 1234–1238.
Supplementary files
![](/img/style/loading.gif)